Axio BioPharma, based in Madison, Wisconsin, has initiated services for recombinant protein manufacturing, including monoclonal antibody production. Operating from Forward BIOLABS, the company aims to support biologics development by offering high-quality protein production capabilities.
PR NewswireForward BIOLABS, with backing from the Wisconsin Economic Development Corporation, has selected 15 early-stage biohealth companies for its 2024 Forward Membership Program. The program provides access to fully equipped co-working labs, resources, and a supportive community to accelerate innovation. Notably, 74% of the selected startups are led by women or minorities, emphasizing the program's commitment to diversity.
Forward BIOLABSeMBR Genomics has partnered with Axio BioPharma to manufacture and distribute MKLP1 Pro™ antibodies, targeting advancements in cancer diagnostics. The antibodies, available in IgM and IgG formats, are designed to facilitate research into midbody remnants and large extracellular vesicles, potentially leading to non-invasive early cancer detection methods.
PR NewswireIn a WisBusiness podcast episode, Justin Byers, CEO of Axio BioPharma, elaborates on the company's use of AI to streamline protein manufacturing processes. By integrating AI into process development, Axio aims to reduce time and costs for clients. The company plans to expand its production capacity and workforce in Madison, Wisconsin.
WisBusinessPeachscore has announced the inclusion of 87 startups across 23 industries into its Data-Driven Accelerator Program. Participants, including companies in biotechnology, healthcare, and sustainable energy, will receive mentorship, resources, and access to Peachscore's acceleration platform to aid in scaling and securing funding.
GlobalNewswire